In a report released today, Brett Fishbin from KeyBanc maintained a Buy rating on Resmed (RMD – Research Report), with a price target of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback